CardioMech — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

CardioMech is pioneering a catheter-based solution for mitral regurgitation (MR), a prevalent and serious cardiovascular disease. Its core technology is an artificial chord delivery system (MVRS) implanted via a transfemoral, transseptal route on a beating heart, targeting a simpler procedure than current surgical or transcatheter options. The company is in the clinical stage with an Early Feasibility Study, positioning itself in a large and growing market expected to surpass the TAVR market. As a private, pre-revenue entity, its success hinges on clinical validation, regulatory approval, and navigating a competitive landscape dominated by established players.

Cardiovascular

Technology Platform

Transcatheter Mitral Valve Repair System (MVRS) for implanting artificial chords via percutaneous, transfemoral, transseptal access on a beating heart.

Opportunities

The mitral regurgitation treatment market is larger and less penetrated than the multi-billion dollar TAVR market, representing a massive addressable patient population.

CardioMech's simpler, anatomy-restoring artificial chord approach could position it as a first-line therapy for a broader range of patients, including younger, healthier individuals currently in 'watchful waiting.'.

Risk Factors

The company faces intense competition from established players like Abbott (MitraClip) and Edwards Lifesciences, high clinical and regulatory hurdles for its unapproved device, and significant financial dependency on venture funding as a pre-revenue entity.

Competitive Landscape

The transcatheter mitral repair market is dominated by Abbott's MitraClip, with Edwards Lifesciences' Pascal and Cardioband as key competitors. CardioMech competes by offering an artificial chordal repair solution versus leaflet clipping or annular remodeling, aiming for procedural simplicity and anatomical restoration. It must differentiate on clinical outcomes, ease of use, and cost to gain traction.

More companies in Drug Delivery & Formulation →More companies in Norway →